Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations
NCT01736891Phase 3Completed
- Sponsor
- Chongqing Fortune Biomedical Technology Co., Ltd.
- Start
- Nov 2011
- Primary completion
- Jun 2013
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Rasagiline with Placebo (2 arms). Primary endpoint: Mean total daily OFF time at 14 weeks. Started Nov 2011; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01736891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01736891.